Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 10.54
-0.284 %
$ 1.71 B
Market Cap
-527.0
P/E
1. INTRINSIC VALUE
Balance Sheet
Certara, Inc.
| Current Assets | 311 M |
| Cash & Short-Term Investments | 179 M |
| Receivables | 119 M |
| Other Current Assets | 12.6 M |
| Non-Current Assets | 1.26 B |
| Long-Term Investments | 0 |
| PP&E | 16 M |
| Other Non-Current Assets | 1.25 B |
| Current Liabilities | 146 M |
| Accounts Payable | 3.5 M |
| Short-Term Debt | 8.31 M |
| Other Current Liabilities | 134 M |
| Non-Current Liabilities | 370 M |
| Long-Term Debt | 304 M |
| Other Non-Current Liabilities | 66.8 M |
EFFICIENCY
Earnings Waterfall
Certara, Inc.
| Revenue | 385 M |
| Cost Of Revenue | 155 M |
| Gross Profit | 231 M |
| Operating Expenses | 232 M |
| Operating Income | -1.73 M |
| Other Expenses | 10.3 M |
| Net Income | -12.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Certara, Inc.
| Net Income | -12.1 M |
| Depreciation & Amortization | 68 M |
| Capital Expenditures | -1.62 M |
| Stock-Based Compensation | 34.8 M |
| Change in Working Capital | 0 |
| Others | 2.4 M |
| Free Cash Flow | 78.8 M |
Wall Street Analysts Price Targets
Certara, Inc.
Wall Street analysts predict an average 1-year price target for CERT of $15 , with forecasts ranging from
a
low of
$13 to a high of $16 .
CERT Lowest Price Target
Wall Street Target
13 USD
23.34%
CERT Average Price Target
Wall Street Target
15 USD
42.31%
CERT Highest Price Target
Wall Street Target
16 USD
51.80%
4. DIVIDEND
ANALYSIS
CERT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Certara, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
59.7 K USD 1
9-12 MONTHS
578 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Joe Vruwink - Baird Scott Schoenhaus - KeyBanc Capital Markets David Windley - Jefferies Dan Leonard - UBS Jeff Garro - Stephens Christine Rains - William Blair Constantine Davides - Citizens Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2025 Earnings Conference Call.
seekingalpha.com
- 1 month ago
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago.
zacks.com
- 1 month ago
Certara Reports First Quarter 2025 Financial Results
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025.
globenewswire.com
- 1 month ago
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
globenewswire.com
- 1 month ago
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
3 Momentum Stocks That Could Soar Post-Market Volatility
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
marketbeat.com
- 2 months ago
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
benzinga.com
- 2 months ago
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies.
globenewswire.com
- 2 months ago
Buy Certara After The FDA Announcement
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials.
seekingalpha.com
- 2 months ago
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
- 2 months ago
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
benzinga.com
- 2 months ago
8. Profile
Summary
Certara, Inc. CERT
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 1.71 B
Dividend Yield
0.00%
Description
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Contact
100 Overlook Center, Princeton, NJ, 08540
https://www.certara.com
IPO
Date
Dec. 11, 2020
Employees
1487
Officers
Mr. John E. Gallagher III
SVice President, Principal Accounting Officer & Chief Financial Officer
Ms. Sheila Rocchio MBA
Chief Marketing Officer
Ms. Rona Anhalt
Chief Human Resources Officer
Mr. Ron DiSantis
Senior Vice President of Corporate Development
Dr. Frederic Yves Bois Ph.D., Pharm.D.
Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board
Dr. William F. Feehery Ph.D.
Chief Executive Officer & Director
Dr. Robert P. Aspbury Ph.D.
President of Certara Predictive Technologies
Dr. David Mitchell Ph.D.
Senior Vice President of Strategic Engagement
Mr. Leif E. Pedersen
President & Chief Commercial Officer
Mr. Daniel D. Corcoran
Senior Vice President & General Counsel